Drug therapy is typically recommended for the initial treatment of patients with atrial fibrillation, but new research suggests there could be a more effective way.
Treatment with empagliflozin for six months was associated with several key improvements. This suggests that, yes, SGLT2 inhibitors can be recommended for HFrEF patients who don't have diabetes.
Anthony S. Fauci, MD, a central figure in the White House Coronavirus Task Force, spoke at length about COVID-19 during the AHA's Scientific Sessions 2020 virtual meeting.